Tariffs Drive Another Market Meltdown
A rapidly escalating trade war has socked stocks as investors weigh the fallout from President Trump’s tariff barrage.
Endpoints News8h
No­vo Nordisk ad­justs its lead­er­ship team; Dyne alums mi­grate to Cres­cent Bio­phar­ma
Camilla Sylvest has moved on from Novo Nordisk after 28 years with the Danish pharma, including more than seven years as EVP ...
Novo Nordisk's head of commercial strategy steps down
Novo Nordisk's head of commercial strategy and corporate affairs, Camilla Sylvest, has decided to leave the company, the ...
Fierce Pharma1d
Novo's commercial strategy head hits the exit, prompting a slew of executive team shakeups
Novo Nordisk is shaking up its executive team as it bids adieu to its longtime head of commercial strategy and corporate ...
European Medical Journal1d
Novo Nordisk announces significant leadership reshuffle
Novo Nordisk has announced major leadership changes, with EVP Camilla Sylvest departing and Ludovic Helfgott taking on an ...
Camilla Sylvest to leave Novo Nordisk after 28 years, Bloomberg reports
Novo Nordisk (NVO) executive Camilla Sylvest is departing the drugmaker after 28 years, Bloomberg’s Sara Sjolin reports. Sylvest has served as ...
Novo Holdings' earnings nearly doubled in 2024, despite Novo Nordisk's stock slump
Novo Holdings, the controlling shareholder of Ozempic-maker Novo Nordisk (NVO), nearly doubled its annual income and ...
Novo Nordisk A/S: Rybelsus (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025
Rybelsus® reduced major adverse cardiovascular events by 14% vs placebo in adults with type 2 diabetes and cardiovascular and/or chronic kidney disease in the SOUL cardiovascular outcomes trial1.Data ...